News
-
23.06.2009
Salvacyl®, developed by Debiopharm, is launched in two European countries - a new therapeutic avenue for the treatment of sexual deviations - -
18.06.2009
Debiopharm Group and Moffitt Cancer Center sign development and commercialisation agreement for small molecule Debio 0928 in early preclinical development for treatment of solid tumours - A novel drug with potential to block cancer cell proliferation
| Partners |
|
At Debiopharm Group, we have dedicated alliance managers to look after our partners. Disclosed principal partners include:
Aché, Aurigene, CAT, Dr. Reddy’s Laboratories, EMS Sigma Farma, Ferring, Ipsen, Kirin, LG Life Sciences, Medical futures, Nagoya University, NanoCarrier, Pfizer, Pharmaleads, Ranbaxy, Rowfarma, Salix, sanofi-aventis, Sidus, sigma-tau, TcLand, Tecnofarma, Tulane University, Tzamal Bio-Pharma,Yakult, Watson Pharmaceuticals
|